On July 26–27, the "2026 Veterinary Drug Management Policy and Inspection & Testing Technology Capability Enhancement" specialized training was held in Taiyuan. The event was hosted by the Shanxi Provincial Inspection and Testing Center (Shanxi Institute of Standard Measurement and Technology). Enhe Pharmaceutical attached great importance to this learning opportunity and participated fully throughout the program.

Focusing on GMP Operations, Strengthening Compliance Foundations

2026 marks the first large-scale re-verification cycle following the implementation of the new version of Veterinary Drug GMP. During the training, experts provided in-depth analysis of common issues and improvement directions in GMP operations, and interpreted the new regulatory requirements for computerized system management.

Enhe Pharmaceutical passed the new version of Veterinary Drug GMP certification in 2023, and has since passed both the High-Tech Enterprise re-verification and the ISO9001 Quality Management System re-verification. Enhe consistently controls every production process with high standards and strict requirements, ensuring that every batch of products stands up to inspection.

Focusing on Companion Animal Medication, Expanding Innovative Pathways

With the rapid growth of the pet economy, registration policies for companion animal veterinary drugs continue to improve. The training systematically reviewed the latest registration progress and development trends for companion animal veterinary drugs, providing clear policy guidance for the company to enter emerging markets and enrich its product lines.

Enhe's "Qianchong" brand has already established a presence in pet disinfection products and moxibustion care, with technical R&D support from Zhuoxin Research Institute. The company will continue to deepen its presence in the companion animal health sector. 

Three production lines under construction at Langxin Biotechnology — semi-solid companion animal compound feed, solid pet premix, and liquid pet premix — are scheduled to begin operation by the end of 2026, laying an industrial foundation for Enhe's expansion into the terminal pet food sector.

Zhuoxin Research Institute & Qianchong

Refining Testing Technology, Building a Strong Quality Defense

The training provided systematic instruction on the basic principles of High-Performance Liquid Chromatography (HPLC), common troubleshooting analysis, and key points for data backup, restoration, and verification. This effectively enhanced the company's inspectors' practical capabilities and data management level, ensuring that every test report is scientific, accurate, and traceable.

Enhe Pharmaceutical has built its own testing center, equipped with functional areas including a sterile room, positive control room, and microbial limit room. Its testing capabilities cover key indicators across the entire veterinary drug production process, ensuring that every stage from raw materials to finished products remains under strict monitoring and continuously safeguarding product quality.

With the integrity of Shanxi merchants and the inheritance of fine traditions, Enhe Pharmaceutical takes root in Shanxi and integrates its traditional spirit of honesty into every stage of modern pharmaceutical manufacturing — from raw material intake to finished product release, from process optimization to testing control — making medicine with conscience and craftsmanship.

We thank the Provincial Inspection and Testing Center for providing this valuable learning and exchange platform, which has greatly supported the continuous improvement of our quality control capabilities. In the future, Enhe Pharmaceutical will continue to be driven by technological innovation and grounded in quality and safety, contributing "Enhe strength" to the cause of animal health. Enhe is committed to becoming a long-term strategic partner trusted by customers, proud of its employees, and respected by society.